These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18842915)

  • 1. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.
    Sandhaus RA; Turino G; Stocks J; Strange C; Trapnell BC; Silverman EK; Everett SE; Stoller JK;
    Chest; 2008 Oct; 134(4):831-834. PubMed ID: 18842915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.
    Barjaktarevic I; Miravitlles M
    BMC Pulm Med; 2021 Mar; 21(1):99. PubMed ID: 33757485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α1-Antitrypsin Deficiency.
    Hatipoğlu U; Stoller JK
    Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-1 antitrypsin augmentation therapy.
    Wewers MD; Crystal RG
    COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency.
    Mordwinkin NM; Louie SG
    Expert Opin Pharmacother; 2007 Oct; 8(15):2609-14. PubMed ID: 17931094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
    Lieberman J
    Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.
    Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R
    COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.
    Chiuchiolo MJ; Crystal RG
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4(Suppl 4):S352-69. PubMed ID: 27564673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
    McElvaney NG
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S191-6. PubMed ID: 27115956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
    Balbi B; Ferrarotti I; Miravitlles M
    Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency.
    Blanco I; Canto H; de Serres FJ; Fernandez-Bustillo E; Rodríguez MC
    J Rheumatol; 2004 Oct; 31(10):2082-5. PubMed ID: 15468381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation therapy for alpha(1)-antitrypsin deficiency.
    Juvelekian GS; Stoller JK
    Drugs; 2004; 64(16):1743-56. PubMed ID: 15301559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
    Tonelli AR; Brantly ML
    Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha(1)-antitrypsin deficiency therapy : pieces of the puzzle.
    Sandhaus RA
    Chest; 2001 Mar; 119(3):676-8. PubMed ID: 11243938
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.
    Schneider CV; Hamesch K; Gross A; Mandorfer M; Moeller LS; Pereira V; Pons M; Kuca P; Reichert MC; Benini F; Burbaum B; Voss J; Gutberlet M; Woditsch V; Lindhauer C; Fromme M; Kümpers J; Bewersdorf L; Schaefer B; Eslam M; Bals R; Janciauskiene S; Carvão J; Neureiter D; Zhou B; Wöran K; Bantel H; Geier A; Dirrichs T; Stickel F; Teumer A; Verbeek J; Nevens F; Govaere O; Krawczyk M; Roskams T; Haybaeck J; Lurje G; Chorostowska-Wynimko J; Genesca J; Reiberger T; Lammert F; Krag A; George J; Anstee QM; Trauner M; Datz C; Gaisa NT; Denk H; Trautwein C; Aigner E; Strnad P;
    Gastroenterology; 2020 Aug; 159(2):534-548.e11. PubMed ID: 32376409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
    Louie SG; Sclar DA; Gill MA
    Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
    Abboud RT; Ford GT; Chapman KR
    Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
    Campos MA; Lascano J
    Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
    Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
    Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.